Spero Therapeutics (NASDAQ:SPRO) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright also issued estimates for Spero Therapeutics’ Q3 2024 earnings at ($0.38) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.38) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($1.08) EPS.

Spero Therapeutics Stock Performance

Shares of Spero Therapeutics stock remained flat at $1.26 during trading on Tuesday. 16,927 shares of the stock were exchanged, compared to its average volume of 220,178. Spero Therapeutics has a 12 month low of $0.99 and a 12 month high of $1.89. The firm has a 50-day simple moving average of $1.37 and a 200-day simple moving average of $1.51. The company has a market cap of $68.03 million, a P/E ratio of 2.93 and a beta of 0.63.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Monday, August 5th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Spero Therapeutics had a net margin of 14.74% and a return on equity of 25.67%. The company had revenue of $10.20 million for the quarter, compared to the consensus estimate of $9.80 million. During the same period in the previous year, the firm earned ($0.23) earnings per share. As a group, analysts predict that Spero Therapeutics will post -1.27 EPS for the current fiscal year.

Institutional Trading of Spero Therapeutics

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in shares of Spero Therapeutics during the 1st quarter valued at $31,000. Acadian Asset Management LLC lifted its stake in Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after purchasing an additional 418,742 shares in the last quarter. Murchinson Ltd. boosted its holdings in shares of Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Spero Therapeutics during the fourth quarter valued at about $1,570,000. Finally, Vanguard Group Inc. lifted its position in shares of Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after buying an additional 9,675 shares in the last quarter. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.